Affiliation: University of Cambridge
- Survival from lung cancer in England and Wales up to 2001Y K Zee
Department of Oncology, University of Cambridge, Box 193 Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, Cambridge, UK
Br J Cancer 99:S43-6. 2008
- Everolimus - a new approach in the treatment of renal cell carcinomaG Anandappa
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Cancer Manag Res 2:61-70. 2010..9 months in the placebo arm). The most common adverse events were stomatitis, pneumonitis, fatigue and infections. We review Phase I-III data with a particular emphasis on safety data and patient focused outcomes...
- Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancerTim Eisen
Department of Oncology, Addenbrooke s Hospital, Cambridge CB2 0QQ, United Kingdom
Lung Cancer 64:60-5. 2009..v.) infusion of 3.2mg/m(2) to patients with small cell lung cancer (SCLC) who relapsed or progressed after one line of chemotherapy...
- Targeted therapies for renal cell carcinoma: review of adverse event management strategiesTim Eisen
Cambridge University Health Partners, Cambridge, UK
J Natl Cancer Inst 104:93-113. 2012..However, because the evidence for the suggested management strategies is largely anecdotal, there is a need for further systematic investigation of management strategies for AEs related to targeted therapies for RCC...
- Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanomaTim Eisen
Department of Oncology R4, Addenbrooke s Hospital, Cambridge, UK
Melanoma Res 19:185-92. 2009..No severe neutropenia was reported. Plitidepsin showed a minor degree of antitumor activity in patients with refractory advanced malignant melanoma. Further evaluation of plitidepsin in combination schedules may be warranted...
- Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinomaKamarul Zaki
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Curr Oncol Rep 15:91-7. 2013..Further assessment of regorafenib should exploit the drug's ability to inhibit mechanisms of escape from anti-angiogenic treatment through biomarker-driven clinical trials...
- Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen
Cambridge University Health Partners, Cambridge, UK
Lancet Oncol 13:1055-62. 2012..This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell carcinoma...
- Tivozanib for the treatment of metastatic renal cancerHan Hsi Wong
Cambridge University Health Partners, Addenbrooke s Hospital, Cambridge, UK
Expert Rev Anticancer Ther 13:649-60. 2013..This article examines tivozanib from its laboratory to clinical development, as well as its relevance and future role in the treatment of RCC in the era of the tyrosine kinase inhibitors...
- Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II studyTim Eisen
Cambridge University Health Partners, Addenbrooke s Hospital, Cambridge, CB2 0QQ, UK
Invest New Drugs 31:1283-93. 2013....
- Adjuvant therapy in renal cell carcinoma-past, present, and futureTobias Janowitz
Department of Oncology, Cambridge University Biomedical Research Campus, Addenbrooke s Hospital, Cambridge, United Kingdom
Semin Oncol 40:482-91. 2013..Additionally, we identify potential future adjuvant trial treatments and propose an alternative design for future adjuvant clinical trials. ..
- Impact of anti-angiogenic treatments on metastatic renal cell carcinomaNicola L Ainsworth
Oncology Centre, Addenbrookes Hospital, Hills Road, Cambridge, CB2 0QQ, UK
Expert Rev Anticancer Ther 9:1793-805. 2009..Many agents are in development for treatment of mRCC, including axitinib in Phase III trials. We will review these treatments, their toxicities and how these targeted agents have impacted on mRCC...
- Perspectives in drug development for metastatic renal cell cancerBristi Basu
University Department of Oncology, Addenbrooke s Hospital, University of Cambridge, Cambridge, CB2 2QQ, UK
Target Oncol 5:139-56. 2010..The challenge of maintaining durable responses from our current therapies persists and this review highlights the plethora of options now available in RCC treatment and the directions in which modern management are heading...
- Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor eraSwethajit Biswas
Department of Oncology, Oncology Centre, Addenbrooke s Hospital, Cambridge, UK
Oncologist 14:52-9. 2009..Overall, two principal questions need addressing. First, is cytoreductive nephrectomy necessary in the TKI era? Second, if so, what is the most appropriate scheduling of TKI therapy with cytoreductive nephrectomy?..
- Does immunotherapy still have a role in treating kidney cancer?Tim Eisen
Department of Oncology, Box 193 R4, University of Cambridge, Cambridge CB9 9AU, United Kingdom
Discov Med 8:165-7. 2009..This article summarizes promising novel immunotherapeutic techniques to identify those patients who will benefit and to optimize outcomes for patients using novel immunotherapeutic approaches...
- Targeting multiple kinase pathways: a change in paradigmLucy Gossage
CRUK Cambridge Research Institute, Addenbrooke s Hospital, Cambridge, United Kingdom
Clin Cancer Res 16:1973-8. 2010..In this review we discuss the principles of specifically targeting multiple kinase pathways with particular reference to angiogenic signaling pathways...
- An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinomaLucy Gossage
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
Hum Mol Genet 23:5976-88. 2014..We use symphony to generate predictions for risk of ccRCC for all possible VHL missense mutations and present these predictions, in association with clinical and experimental data, in a publically available, searchable web server. ..
- The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI dataAndrew B Gill
Department of Radiology, Box 218, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medical Physics, Box 152, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK Electronic address
Magn Reson Imaging 33:246-51. 2015..This simple method for visualisation of errors in DCE-MRI could be used as a routine quality-control technique and also has the potential to reveal otherwise hidden patterns of failure in PK model applications...
- VHL, the story of a tumour suppressor geneLucy Gossage
1 Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK 2 Department of Oncology, University of Cambridge, Box 193, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK 3 Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK
Nat Rev Cancer 15:55-64. 2015..As our understanding of the importance of VHL matures, it is timely to review progress from its initial description to current knowledge of VHL biology, as well as future prospects for novel medical treatments for VHL disease and ccRCC...
- Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinomaLucy Gossage
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Genes Chromosomes Cancer 53:38-51. 2014..Our results support those of recent publications pointing towards a role for BAP1 and PBRM1 mutations in risk stratifying ccRCCs. Further investigation of noncoding alterations in VHL is warranted...